Merck & Co., Inc. (NYSE:MRK) is included in our list of the 10 Most Undervalued Value Stocks to Buy Now. On August 12, 2025, ...

Merck has begun the 8% reduction of its workforce—an initiative that the company revealed two weeks ago—with the dismissal of ...

We recently published 10 Stocks Jim Cramer Discussed As He Questioned Official Data. Merck & Co., Inc. (NYSE:MRK) is one of ...

Merck’s second quarter performance aligned with Wall Street’s revenue expectations but drew a negative reaction from the ...

Merck trades at a low P/E with strong financials, Keytruda growth, and a solid 3.9% yield, while its pipeline offsets future risks. Read why MRK stock is a buy.

Merck puts 1,000-plus Zostavax lawsuits to bed after plaintiffs file for dismissal By Fraiser Kansteiner Jul 8, 2024 10:28am Merck & Co. Zostavax Lawsuits drug safety ...

Meanwhile, mRNA vaccine maker Moderna is cutting around 500 jobs (10% of its workforce) as part of a commitment to save $1.5 ...

As Merck & Co. | As Merck & Co. rolls out a widespread cost-cutting initiative, the pharma is dropping an autoimmune asset acquired a few years ago in a nearly $2 billion biotech takeover.

Merck & Co.'s peptides could be undergoing a transformation into oral tablets thanks to a $493 million licensing deal the company inked with Austria-based drug delivery technology maker Cyprumed.

Merck's Phase 3 trial shows Keytruda plus Padcev improves survival in muscle-invasive bladder cancer patients ineligible for ...

This week, Merck filed a notice in accordance with New Jersey's WARN Act, indicating it plans to eliminate 58 positions at ...

Merck faces a class-action lawsuit over alleged misrepresentation of its mumps vaccine potency, claiming anticompetitive practices to maintain market dominance. Despite ethical concerns, the court ...